trial

Minocycline Augmentation in Schizophrenia

NCTId NCT01561742
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Unknown
Enrollment 120 (estimated)
Sponsored by The University of Texas Health Science Center, Houston
Primary completion 2015-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Unknown
Enrollment
120 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2012-02
Primary completion
2015-01
Eligibility
ALL · 18 Years · 35 Years

Interventions & indications

Drugs
Minocycline

Sponsors

The University of Texas Health Science Center, HoustonLead Sponsor
Stanley Medical Research InstituteCollaborator

Investigators

1
Mujeeb U Shad, MD, MSCSPrincipal Investigator

Sites

1 total
Houston, United States

Facts & assertions

4 sourced
Enrollment
120
Phase
NA
Primary Completion Date
2015-01
Status
UNKNOWN
relationships
The graph out of here
drug
Minocycline
drug
lead_sponsor
The University of Texas Health Science Center, Houston
company
collaborator
Stanley Medical Research Institute
company
indication
Schizophrenia
indication
Schizophrenia
indication
cyclopia sequence
indication
investigator
Mujeeb U Shad, MD, MSCS
person